Investigator and Site : Final Protocol

Investigator and Site : Final Protocol

Trial Design Stage

Published Date: April 29, 2025

Share to:

Helpful Terms and Definitions

ClinicalTrials.gov Glossary Terms

NIH Glossary of Common Terms

FDA Drug Development and Review Definitions

Resources

Final Protocol

What study metrics can be shared across sites to motivate site staff?

Questions To Ask

open drawer
  • How will data be collected, stored, and managed?
  • How does the size of the site and amount of study personnel effect the study?
  • Do all planned sites have the same available resources?

Why involve Investigators and Sites now?

As your study enters the final protocol phase, investigators and sites become essential partners in ensuring the protocol is feasible, practical, and ready for execution. Early and active communication enables sites to:

  • Plan for enrollment, retention, and protocol compliance
  • Prepare for data entry, query resolution, and operational oversight
  • Clarify study expectations before activation
  • Begin training and workflow integration
  • Build momentum and shared ownership going into study launch

This final‑protocol engagement stage closes the loop on the earlier site‑selection work (mapping disease prevalence, identifying KOLs, building advisory networks) and ensures sites selected earlier remain fully activated partners.

It supports:

  • Realistic operational planning
  • Diversity and inclusion goals
  • Stronger partnerships with community + academic centers
  • Better execution once the study begins

Sponsors that engage sites at this point consistently see smoother startup and stronger study conduct.

What aspects of the final protocol should they inform?

Even at the final protocol stage, investigators and sites provide critical real‑world insights.

They Should Inform:

  • Operational feasibility of visit schedules
  • Participant burden and recruitment considerations
  • Clarity needed in procedures, assessments, or timing
  • Potential barriers for diverse and underrepresented populations
  • Implementation of any protocol amendments

Sponsors should share any protocol amendments—however minor—through open, active communication with all investigators and sites to maintain alignment.

How can I build a feedback loop with investigators and sites?

A structured feedback loop ensures sites can raise practical issues without reopening major scientific decisions.

1. Define What Is Open for Feedback

2. Give Sites a Simple, Targeted Way to Respond

3. Review Feedback Rapidly

4. Close the Loop

5. Use Micro Advisory Touchpoints

6. Keep the Process Time Bound

What should sponsors do at the Final Protocol stage?

Distribute the Final Protocol

Provide investigators and site teams with the final protocol as soon as it is approved. This ensures everyone has the same reference document and reduces procedural inconsistencies across the network.

Host Study Kick‑Off Meetings and Trainings

Use this stage to align all key partners—including quality, data management, safety teams, and site staff.
Activities may include:

  • Investigator meetings or webinars
  • Protocol walk‑throughs
  • Technology platform trainings
  • Clinical assessment / procedure trainings
  • Adverse event and reporting training

Communicate Expectations Clearly

Provide sites with concise summaries, checklists, and timelines for:

  • Startup activities
  • Data entry requirements
  • Safety reporting
  • Essential document submission
  • Scheduling of initiation visits

Create Rapid Response Pathways/Escalation

  • Ensure the site knows exactly who to call at the Sponsor/CRO when a critical issue arises

If a CTQ factor, like a specific imaging requirement, is causing patients to drop out, the site must flag this so the Sponsor can adjust the strategy before it impacts the whole study

Investigator and Site Resources